Amy Mehta
Pulmonary Disease · Bakersfield, CANPI 1558553347
Payments from drug & device makers
Across 198 payments — averaging $27.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$2K
- GSK$656
- Actelion Pharmaceuticals US, Inc.$583
- Boehringer Ingelheim$414
- AstraZeneca$323
- Intuitive Surgical$176
- plus $1K from 23 others
What the payments were for
- Travel & lodging$1,91135%
- Food & beverage$3,55765%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 13 | $2,015 |
| GSK | 42 | $656 |
| Actelion Pharmaceuticals US, Inc. | 25 | $583 |
| Boehringer Ingelheim | 24 | $414 |
| AstraZeneca | 21 | $323 |
| Intuitive Surgical | 2 | $176 |
| Sunovion Pharmaceuticals Inc. | 12 | $164 |
| Genentech USA, Inc. | 7 | $137 |
| Regeneron Healthcare Solutions, Inc. | 4 | $96 |
| Insmed, Inc. | 5 | $92 |
| Advanced Respiratory, Inc | 5 | $90 |
| Sun Pharmaceutical Industries Inc. | 4 | $86 |
| Mylan Specialty L.p. | 4 | $81 |
| Pfizer | 4 | $72 |
| United Therapeutics Corporation | 3 | $65 |
| Outset Medical Inc | 1 | $61 |
| Novartis | 4 | $54 |
| Bayer | 4 | $53 |
| Mayne Pharma Commercial LLC | 2 | $44 |
| Merck | 2 | $37 |
| Tactile Systems Technology Inc | 1 | $36 |
| Inari Medical, Inc. | 1 | $35 |
| Grifols USA, LLC | 2 | $30 |
| Philips North America LLC | 1 | $22 |
| Astellas Pharma US Inc | 1 | $17 |
| Circassia Inc. | 1 | $14 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $12 |
| Monaghan Medical Corporation | 1 | $11 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,487 in reported general payments places this provider in the 65th percentile of 1,261 pulmonary disease providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Spiriva RespimatTiotropium Bromide | 242 | $95,888 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 168 | $65,138 |
| Wixela InhubFluticasone Propion/Salmeterol | 236 | $33,538 |
| AlvescoCiclesonide | 120 | $27,920 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $23,311 |
| EliquisApixaban | 15 | $20,340 |
| BreynaBudesonide/Formoterol Fumarate | 72 | $11,916 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 181 | $3,720 |
| Atovaquone | 12 | $3,304 |
| Fluconazole | 29 | $1,264 |
| Fluticasone Propionate | 63 | $1,127 |
| Prednisone | 127 | $1,006 |
| Azelastine Hcl | 36 | $905 |
| Azithromycin | 31 | $830 |
| Ethambutol Hcl | 14 | $829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $414 | $161,026410 claims |
| GSKTrelegy Ellipta | $656 | $23,31130 claims |
| PfizerEliquis | $72 | $20,34015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,261 pulmonary disease providers in California.
Other pulmonary disease in Bakersfield
- Toby MaherLos Angeles$27.6M
- David PhamWestminster$5.9M
- Andrew WachtelLos Angeles$5.9M
- Aaron WeinbergIrvine$5.1M
- Michael RothLos Angeles$4.5M
- Namita SoodSacramento$3.7M
- Edward FedermanSan Diego$3.6M
- Sanjay VadgamaSherman Oaks$3.3M
- Rajan SaggarLos Angeles$3.3M
- Samuel LouieSacramento$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.